Phase 1/2Data readout

LSTA1 + gemcitabine/nab-paclitaxel

Pancreatic cancer

LSTALisata Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: LSTA1 + gemcitabine/nab-paclitaxel
Development stage: Phase 1/2
Event type: Data readout
Indication: Pancreatic cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for LSTA1 + gemcitabine/nab-paclitaxel in Pancreatic cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

Partnered w/ Qilu Pharma. 4/23/24- First patient dosed in Ph2 trial in China. 4/16/25- Enrollment completed w/ trial data in the coming months. 11/06/25:- Qilu Phase2 trial data expected 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source